CTY news

Latest 1 stories · newest Nov 10, 2026

CTY

City Therapeutics announces first patient dosed in City-Rbp4 Phase 1 trial

City Therapeutics dosed the first participant in a Phase 1 clinical trial of CITY-RBP4, targeting Stargardt disease. The trial aims to evaluate safety, tolerability, and pharmacodynamics with initial data expected in mid-2027.

Other Nov 10, 2026 sentiment +0.20 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same CTY feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/CTY/newsSTART FREE